Biocon-Equillium tie-up: Will it boost the shares

| Updated on December 12, 2019


Biocon and Equillium Inc on Thursday announced the expansion of their collaboration and license agreement for itolizumab to grant the latter exclusive rights for developing and commercialising the product in Australia and New Zealand. Equillium had originally secured exclusive rights to develop and commercialise Biocon’s novel biologic, itolizumab, for the US and Canada, in May 2017. The drug is indicated for treatment of moderate to severe plaque psoriasis.

Published on December 13, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like